Conceived and led a holistic, research-centred breast cancer service (from 2001), one of the UK’s most comprehensive, including a dedicated secondary breast cancer workstream.
Secured £9 million funding to introduce adjuvant trastuzumab (Herceptin) before NICE approval, establishing national cardiac monitoring guidelines.
Implemented adjuvant bisphosphonates (2016) across Greater Manchester to improve survival and equity of access.
Led the design and implementation of the first electronic systemic anti-cancer therapy (SACT) prescribing system in Greater Manchester.
Developed innovative models of outreach care – SACT delivery in district hospitals, GP surgeries, hospices, and at home.
Internationally recognised as a principal investigator and UK chief investigator for major trials: PERSEPHONE, tAnGo, plasmaMATCH, EPHOS-B, HER-2-RADiCAL, CHAT.
Founding Co-Director of the Manchester Breast Centre (2005), building one of Europe’s foremost translational research hubs.
Co-founder of the AstraZeneca–University of Manchester–Christie Alliance, precursor to the Manchester Cancer Research Centre.
Chair, NCRI Breast Research Group (2020–2022) and Chair, WG2 Metastatic Breast Cancer (2022–present).
Over 300 peer-reviewed publications, with an h-index of 57, including practice-changing trials published in The Lancet and New England Journal of Medicine.
Medical Director, NIHR Manchester Clinical Research Facility:
Secured £4.5M (2012) and £12.5M (2016) NIHR grants.
Led the first UK CRF capable of delivering ATIMP solid cancer trials.
Director of Systemic Anti-Cancer Therapy, Greater Manchester Cancer Alliance (2011–2019): authored and implemented the SACT Strategy for Manchester Cancer.
Clinical expert advisor to NICE for multiple breast cancer technology appraisals and diagnostics.
Longstanding member of NHS England Chemotherapy Clinical Reference Group (2013–2021).
ACCEA National Clinical Excellence Awards: Bronze (2012), Silver (2017).
NIHR Lead Commercial Investigator Award (2015).
Honorary Clinical Chair, University of Manchester (2016).
Selected for the AstraZeneca Future Forum on Breast Cancer (2005).
Invited speaker at ASCO, ESMO, SABCS, EBCC, and other leading international oncology conferences.
Co-author of the 2008 National Curriculum for Medical Oncology.
Training Programme Director, HEE North West Deanery (2008–2011).
Supervised and mentored numerous PhDs, clinicians, and advanced nurse practitioners, several now national leaders.
Innovated Advanced Practitioner Roles (nurse clinicians, ANPs, advanced pharmacy prescribers) in cancer research and systemic therapies.
(2025) Key Contributor to the UK Cancer Plan 2025
(2022) Founder, Cancer Services Ltd developing the first digital global medical second opinion service changing the landscape for NHS services in 2025
(2001) Incorporated his model of care into the European Code of Cancer Practice and NHS service innovations.
(2000-2021) Contributed to AstraZeneca’s early breast cancer strategy for Camizestrant and Capivasertib.
